Ariana Morales
Ariana Morales has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Agustín Palacios-García
Laboratorios Columbia, Mexico
2 shared publications - Berenice Ceron-Trujillo
Aequitas Medica, Mexico
2 shared publications - Coralys Abreu-Rosario
Hospital Angeles Lomas, Mexico
2 shared publications - César Ochoa-Martínez
Center for Clinical Research, WesternU Medical Center at Western University of Health Sciences, Pomona, CA 91766, USA
2 shared publications - Edgar Ramírez-Ramírez
Aequitas Medica, Mexico
2 shared publications - Jorge Vázquez-García
CEADO Centro Especializado en Atención de Diabetes y Obesidad, Miguel Hidalgo 11650, Mexico City, Mexico
2 shared publications
Latest Publications
- Open Access
Expert Consensus on the Appropriateness of Saccharomyces cerevisiae Hydrolysate in Obesity Management Using the RAND/UCLA Appropriateness Method
Nutraceuticals are bioactive compounds with potential roles in disease prevention and treatment. Their accessibility and affordability have driven growing interest in obesity care. Among them, bioactive hydrolysates derived from Saccharomyces cerevisiae show promise, yet clinical guidelines seldom address their use. We aimed to develop a guidance statement on their appropriateness using the RAND/UCLA consensus method. A multidisciplinary panel of ten experts rated the appropriateness of a bioactive hydrolysate derived from Saccharomyces cerevisiae across clinical scenarios relevant to obesity care, informed by a targeted evidence review and conducted using the two-round RAND/UCLA consensus method, with ratings on a 1–9 scale. The panel deemed the use of the bioactive hydrolysate derived from Saccharomyces cerevisiae, in combination with lifestyle modifications, as an appropriate intervention for managing obesity-related outcomes. This included its use in patients with specific comorbidities, as an adjunct to standard pharmacotherapy, and in a set of selected clinical scenarios. Based on evidence and expert consensus, a bioactive hydrolysate derived from Saccharomyces cerevisiae is appropriate across a range of clinical scenarios within comprehensive obesity care. Further studies should evaluate long-term effectiveness, broader populations and combination regimens.
Open AccessExpert Consensus on the Appropriateness of Saccharomyces cerevisiae Hydrolysate in Obesity Management Using the RAND/UCLA Appropriateness Method
Nutraceuticals are bioactive compounds with potential roles in disease prevention and treatment. Their accessibility and affordability have driven growing interest in obesity care. Among them, bioactive hydrolysates derived from Saccharomyces cerevisiae show promise, yet clinical guidelines seldom address their use. We aimed to develop a guidance statement on their appropriateness using the RAND/UCLA consensus method. A multidisciplinary panel of ten experts rated the appropriateness of a bioactive hydrolysate derived from Saccharomyces cerevisiae across clinical scenarios relevant to obesity care, informed by a targeted evidence review and conducted using the two-round RAND/UCLA consensus method, with ratings on a 1–9 scale. The panel deemed the use of the bioactive hydrolysate derived from Saccharomyces cerevisiae, in combination with lifestyle modifications, as an appropriate intervention for managing obesity-related outcomes. This included its use in patients with specific comorbidities, as an adjunct to standard pharmacotherapy, and in a set of selected clinical scenarios. Based on evidence and expert consensus, a bioactive hydrolysate derived from Saccharomyces cerevisiae is appropriate across a range of clinical scenarios within comprehensive obesity care. Further studies should evaluate long-term effectiveness, broader populations and combination regimens.
- Open Access
- 1 September 2025
- Published by MDPI AG in Preprints.org
Expert Consensus on the Appropriateness of Saccharomyces cerevisiae Hydrolysate in Obesity Management Using the RAND/UCLA Appropriateness Method
Background: Nutraceuticals are bioactive compounds that have shown promise in disease prevention and management. Due to their accessibility and affordability, they have gained increasing interest in obesity management. Some such nutraceuticals are Saccharomyces cerevisiae hydrolysates. Despite this growing interest, clinical practice guidelines rarely address their use, leaving clinicians with limited direction of their usage in routine care. This study aimed to develop a general guidance statement on the appropriateness of a Saccharomyces cerevisiae hydrolysate using a RAND/UCLA consensus process. Methods: A multidisciplinary panel of nine experts was convened to evaluate the appropriateness of a Saccharomyces cerevisiae hydrolysate in various clinical scenarios related to obesity management. Results: The panel deemed the use a Saccharomyces cerevisiae hydrolysate, in combination with lifestyle modifications, as an appropriate intervention for managing obesity-related outcomes. This included its use in patients with specific comorbidities, as an adjunct to standard pharmacotherapy, and in a set of selected clinical scenarios. Conclusions: Combining practitioners' insights with available data, the panel reached consensus that a Saccharomyces cerevisiae hydrolysate represents an appropriate intervention in a range of clinical scenarios for obesity management.
- 1 September 2025
- Published by MDPI AG in Preprints.org
Open AccessExpert Consensus on the Appropriateness of Saccharomyces cerevisiae Hydrolysate in Obesity Management Using the RAND/UCLA Appropriateness Method
Background: Nutraceuticals are bioactive compounds that have shown promise in disease prevention and management. Due to their accessibility and affordability, they have gained increasing interest in obesity management. Some such nutraceuticals are Saccharomyces cerevisiae hydrolysates. Despite this growing interest, clinical practice guidelines rarely address their use, leaving clinicians with limited direction of their usage in routine care. This study aimed to develop a general guidance statement on the appropriateness of a Saccharomyces cerevisiae hydrolysate using a RAND/UCLA consensus process. Methods: A multidisciplinary panel of nine experts was convened to evaluate the appropriateness of a Saccharomyces cerevisiae hydrolysate in various clinical scenarios related to obesity management. Results: The panel deemed the use a Saccharomyces cerevisiae hydrolysate, in combination with lifestyle modifications, as an appropriate intervention for managing obesity-related outcomes. This included its use in patients with specific comorbidities, as an adjunct to standard pharmacotherapy, and in a set of selected clinical scenarios. Conclusions: Combining practitioners' insights with available data, the panel reached consensus that a Saccharomyces cerevisiae hydrolysate represents an appropriate intervention in a range of clinical scenarios for obesity management.